German study confirms efficacy of Irish tinnitus therapy

A tinnitus therapy developed by Irish company Neuromod has delivered results in a real-world study.

The independent study by Hannover Medical School’s German Hearing Centre found that 85 per cent of patients experienced a reduction in their tinnitus symptoms when using Neuromod’s Lenire device.

Tinnitus, which is caused when hair cells or nerve fibres in the inner ears are damaged, affects as many as 15 per cent of people to some degree and is often described as a ringing or buzzing in the ears.

Severity of symptoms

The study showed that treatment for between six and 12 weeks with Lenire achieved clinically meaningful improvements in severity of symptoms in a real-world clinical setting.

Patent row between pharma companies referred to European court

---

HealthBeacon system helps patients take medication correctly

---

Lennox buys Meath-based laboratory equipment group

---

Clariant delays 2021 results as it looks into whistleblower claims

---

The results confirms clinical trial data from Neuromod in a study of 326 people.

“Results from real-world studies can turn out to be different from those of clinical trials, for a variety of reasons,” said Neuromod chief executive and founder, Dr Ross O’Neill.

‘Efficacy and safety’

“So it is really encouraging to see that the study performed by Prof Thomas Lenarz’s team showed similar levels of efficacy and safety for the Lenire device as in our own large-scale clinical study.”

Neuromod currently markets its device in Ireland, Germany, Austria, the UK, Switzerland and Belgium.

Neuromod has raised more than €25 million in a series of fundraisings, led by Irish life sciences specialist Fountain Healthcare Partners, to develop and commercialise its product in Europe as well as working towards US approval .